Prevalence and incidence of Parkinson's disease in Europe-Reference-Cited by-同舟云学术

Prevalence and incidence of Parkinson's disease in Europe

Published:2005-08 Issue:4 Volume:15 Page:473-490
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

von Campenhausen Sonja,Bornschein Bernhard,Wick Regina,Bötzel Kai,Sampaio Cristina,Poewe Werner,Oertel Wolfgang,Siebert Uwe,Berger Karin,Dodel Richard

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Clinical Neurology,Neurology,Pharmacology

Reference64 articles.

1. Case ascertainment uncertainties in prevalence surveys of Parkinson's disease;Anderson;Mov. Disord.,1998

2. Pitfalls in neuroepidemiologic research;Anderson;Neuroepidemiology,1998

3. The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti-parkinsonian drugs;Artazcoz Sanz;Rev. Esp. Salud Publica,1995

4. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian longitudinal study on aging;Baldereschi;Neurology,2000

5. Prevalence of PD and other types of Parkinsonism in three elderly populations of central Spain;Benito-Léon;Mov. Disord.,2003

Cited by 432 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update: Descriptive epidemiology of Parkinson disease;Parkinsonism & Related Disorders;2024-01

2. ASO-mediated knockdown or kinase inhibition of G2019S-Lrrk2 modulates lysosomal tubule-associated antigen presentation in macrophages;Molecular Therapy - Nucleic Acids;2023-12

3. TheR1441C-LRRK2mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner;2023-10-17

4. Intracranial arteriosclerosis and the risk of dementia: A population‐based cohort study;Alzheimer's & Dementia;2023-10-09

5. Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial;Parkinsonism & Related Disorders;2023-09